Antimicrobial peptides for therapeutic applications: a review.
Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ. · 2012
Read Antimicrobial peptides for therapeutic applications: a review. by Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6268056.txt.
Introduction
Seo and co-authors review antimicrobial peptides as future medicines. Their review appeared in Molecules. Such peptides occur in many living things as part of innate defence. They kill a broad range of bacteria, fungi, and viruses. Their attack style differs from standard antibiotics. That makes them of interest against drug resistant germs.
Barriers still block clinic and market use. Some peptides can harm human cells. Gut and blood enzymes can chew them up fast. Making them costs a lot per dose. The review focuses on very short peptides, under twelve building blocks. Shorter forms cost less and may dodge some flaws. Links between their shapes and killing power are mapped in detail. Design tricks, such as swapped building blocks, are also covered. The goal is strong action kept in a small, stable form.
Catalog record
| CREATOR | Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ. |
|---|---|
| YEAR | 2012 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Antimicrobial Peptides for Therapeutic Applications: A Review By Min-Duk Seo, Hyung-Sik Won, Ji-Hun Kim, Tsogbadrakh Mishig-Ochir, Bong-Jin Lee Published in: Molecules DOI: 10.3390/molecules171012276 ABSTRACT Abstract Antimicrobial peptides (AMPs) have been considered as potential therapeutic sources of future antibiotics because of their broad-spectrum activities and different mechanisms of action compared to conventional antibiotics. Although AMPs possess considerable benefits as new generation antibiotics, their clinical and commercial development still have some limitations, such as potential toxicity, susceptibility to proteases, and high cost of peptide production. In order to overcome those obstacles, extensive efforts have been carried out. For instance, unusual amino acids or peptido-mimetics are introduced to avoid the proteolytic degradation and the design of short peptides retaining antimicrobial activities is proposed as a solution for the cost issue. In this review, we focus on small peptides, especially those with less than twelve amino acids, and provide an overview of the relationships between their three-dimensional structures and antimicrobial activities. The efforts to develop highly active AMPs with shorter sequences are also described. Keywords: antimicrobial peptides (AMPs), antibiotics, structure-activity relationship (SAR) 1. INTRODUCTION Antimicrobial peptides (AMPs) are endogenous polypeptides produced by multicellular organisms in order to protect a host from pathogenic microbes. AMPs are also defined as host defense peptides because of their essential role in constituting the innate immunity system [1,2,3,4]. AMPs are generally comprised of less than 50 amino acids approximately, and characterized by cationic amphipathic properties. In general, when AMPs are folded in membrane mimetic environments, one side of AMPs is positively charged (mainly due to lysine and arginine residues) and the other side contains a considerable proportion of hydrophobic residues [1,2,5,6]. AMPs show broad-spectrum antimicrobial activities against various microorganisms, including Gram-positive and Gram-negative bacteria, fungi, and viruses [1]. Of particular interest, many AMPs are effective against multi-drug resistant (MDR) bacteria and possess low propensity for developing resistance [7,8,9]. Bacterial resistance to antibiotics can be achieved by diverse routes including inhibition of the drug-target interaction, modification of the drug-binding site in target proteins, and efflux of the drug from target cells [10]. Microorganisms can also alter their genetic patterns in response to environmental changes using their own complex systems called sensor-transducer response systems. For instance, bacteria can modify their gene expression in the presence of AMPs [11]. AMPs possess low propensity for developing resistance, probably due to their distinguished mode of action. Most AMPs, with their amphipathic nature, directly act on the membrane of the pathogen. The cationic properties of AMPs are implicated in their selective interaction with the negatively charged surfaces of microbial membranes, resulting in the accumulation of AMPs on the membrane surface. Then, their hydrophobic portions are responsible for the interaction with hydrophobic components of the membrane. From this complex interaction with the membrane, major rearrangements of its structure occur, which may result from the formation of peptide-lipid specific interactions, the peptide translocation across the membrane and interaction with intracellular targets or the most common mechanism, a membranolytic effect [3,11,12,13,14,15,16]. Such a characteristic mechanism of action, distinct from that of conventional antibiotics, enables AMPs to avoid the common resistance mechanisms observed for classic antibiotics. Consequently, AMPs are receiving great attention as promising alternatives to conventional antibiotics to overcome the current drug resistance crisis. In this review, we describe the advantages and limitations of AMPs as novel antibiotic agents and structural information aids for developing new AMPs. Especially, we focus on small peptides (less than twelve amino acids in length) in clinical trials and their structure-activity relationships (SAR). 2. STRUCTURE-ACTIVITY RELATIONSHIPS (SAR) OF ANTIMICROBIAL PEPTIDES AMPs can be classified into four groups based on their structures: α-helical peptides, β-sheet peptides, extended peptides, and loop peptides [1,2,3,6]. The α-helical AMPs, including magainin, cecropin, and pexiganan, constitute a representative class of AMPs that are the most well established in structure-activity relationships. This group of peptides is usually unstructured in aqueous solution and forms amphipathic helices in membranes or membrane-mimicking environments. Most α-helical AMPs disrupt bacterial membranes, and several mechanisms of action employed by various AMPs have been proposed. The α-helical amphipathic peptides form barrel-like bundles in the bacterial membranes, and these transmembrane clusters line amphipathic pores (barrel-stave model). Many α-helical AMPs, including some magainins and cecropins, can dirupt bacterial membranes by forming carpet-like clusters of peptides. The peptides adsorb and align in parallel to the surface of bacterial membranes, then the membranes are collapsed into micelle-like structures by high concentrations of peptides (carpet model). The α-helical AMPs, such as some magainins and protegrins, form toroidal pores to disrupt the bacterial membranes (toroidal pore model) [1,2,3,4,5,6,7,9,11]. The β-sheet AMPs, such as α-, β-defensins, and protegrin, are stabilized by disulfide bridges, and form relatively rigid structures. Many of β-sheet AMPs exert their antimicrobial activities by disrupting bacterial membranes. They are perpendicularly inserted or tilted into the lipid bilayer to form toroidal pores, and hydrophilic regions of the peptides are associated with the polar head groups of the membranes [3]. The extended AMPs, which are predominantly rich in specific amino acids such as proline, tryptophan, arginine, and histidine, have no regular secondary structure elements. Indolicidin is a tryptophan/proline-rich extended peptide and Bac5 and Bac7 are proline/arginine-rich peptides [17,18]. Many extended AMPs are not active against the membranes of pathogens, but they can achieve their antimicrobial activities by penetrating across the membranes and interacting with bacterial proteins inside [3]. On the other hand, some extended peptides, such as indolicidin, are membrane active and induce membrane leakage. Indolicidin is a 13-amino acid AMP containing five tryptophan and three proline residues. The peptide adopts a poly-L-II helical structure in the presence of liposomes, and the high content of tryptophan residues is responsible for the interaction with lipid membranes [17]. The loop AMPs, including bactenecin, adopt a loop formation with one disulfide bridge. Understanding the structure-activity relationships (SAR) of AMPs is essential for the design and development of novel antimicrobial agents with improved properties. In particular, the atomic level structures of AMPs can provide versatile information for all stages of drug development, including the peptide design and modification for pharmaceutical application. Pexiganan (also known as MSI-78), a synthetic variant of magainin 2, is one of the best-investigated AMPs in terms of drug development [19,20]. Pexiganan has reached clinical trials as a novel topical broad-spectrum antibiotic for the treatment of mild-to-moderate diabetic foot ulcer infections [4,20,21]. The three-dimensional structure of pexiganan, determined by Nuclear Magnetic Resonance (NMR) spectroscopy, revealed that the peptide forms a dimeric antiparallel α-helical structure in the presence of membrane mimetics [22,23]. The atomic resolution structure also demonstrated that the side chains of three phenylalanine residues are important for the self-dimerization [23]. In addition to the peptide structure, its orientation in membrane is critical to understand the exact mode of membrane interaction. A solid-state NMR study of pexiganan suggested that the peptide adopts a helical conformation interacting with the membrane surface and then the dimeric peptide is inserted into the membrane [22]. Knowledge on the functional structures of AMPs also enables a rational design of synthetic model peptides. In this respect, minimalistic de novo approaches to design model amphipathic helical peptides are noteworthy. For example, certain 14- or 15-mer peptides (namely LK peptides) composed of two kinds of amino acids (leucines and lysines), have been